SecBot SecBot

CRVO

CervoMed Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001053691 Biotech & Drug Discovery
$2.22 −0.09 (−3.68%)
Oct 26 4:00 PM ET · prev $2.31
Market cap
$33.9M
Nano cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$15.00
+574% · range $7.00–25.00
Next earnings
Nov 16
in 21 days · EPS est. −$0.50
1 year
−68.3%
from $7.02 · Oct 27
30 days
−16.7%
from $2.67
52-week range
$2.22–9.94
at the low
Avg volume 20D
307.0K
Oct 12 spike 889.6K
Short interest
1.34M
≈8.9% of shares · +9.1%
Days to cover
7.0
at average volume
Insider net
+$3.0M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 7 reports · 90 days
Balance 0 bearish · 4 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/7 ·Next Earnings date, Nov 16, 2026
Strongest BULLISH CervoMed reported initial 12-week biomarker data from its Phase 2a trial of neflamapimod in nfvPPA, showing…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $3.0M at an average $3.14. No open-market sales. Price is 29% below their cost.

  • InstitutionsBEARISH

    Q2 2026: 1 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.585 → −$0.500 over 90 days. 3 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +9.1% to 1.34M shares. 7.0 days to cover, ≈8.9% of shares.

  • TrendDOWNTREND

    15% below its 50-day average. New closing low $2.22 on Oct 26.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 11.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCADD32,231$99.9K
Cetera Investment AdvisersTRIM19,622$60.8K
NORTHERN TRUST CORPTRIM13,318$41.3K
MORGAN STANLEYNEAR_EXIT12,699$39.4K
UBS Group AGNEAR_EXIT992$3.1K
MORGAN STANLEYADD739,892$2.9M
MILLENNIUM MANAGEMENT LLCDOUBLED208,908$823.1K
JANE STREET GROUP, LLCADD18,246$71.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy2Buy9Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +574%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 5, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 12, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 10, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Jul 15, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 13, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 9, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$3.0M
bought · 1 insider
$0
sold · 0 insiders
−29.1%
vs their $3.14 cost
DateInsiderTypeValue
Oct 22, 2026
De Rosch Mark
EVP, RA and GA and PgM
AWARD19,100 sh
Oct 22, 2026
Blackburn Kelly
EVP, Clinical Development
AWARD19,100 sh
Oct 22, 2026
Winton Matthew
Chief Commercial and Business
AWARD19,100 sh
Jun 11, 2026
BOGER JOSHUA S
Director
BUY$3.0M
Jun 11, 2026
BOGER JOSHUA S
Director
BUY955,414 sh
Jun 11, 2026
BOGER JOSHUA S
Director
BUY955,414 sh
Jun 8, 2026
ALAM JOHN J
CEO & President
AWARD8,150 sh
Jun 8, 2026
Hollingsworth Jane H
Director
AWARD8,150 sh

Earnings setup

Estimates
Nov 16
reports in 21 days
−$0.50
EPS estimate, this quarter
+15%
estimate change, 90 days
3↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.50-$0.73–-$0.23+11.9%$50.0K
Next Q-$0.45-$0.75–-$0.11+11.3%$83.3K
Current FY-$2.13-$2.97–-$1.16+3.2%$133.3K
Next FY-$1.39-$1.96–-$0.68+6.1%$833.3K
Reddit
Recent posts
r/stocks Neutral 15d ago
Anyone following CRVO’s FTD presentation today?
1 upvotes · 0 comments
All social signals and their track records

Short side

FINRA· Sep 30, 2026
1,339,771
shares short
+9.1%
vs prior settlement
7.0
days to cover
≈8.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Insider
De Rosch Mark was granted 19,100 shares
EVP, RA and GA and PgM
Oct 22, 2026 Insider
Blackburn Kelly was granted 19,100 shares
EVP, Clinical Development
Oct 22, 2026 Insider
Winton Matthew was granted 19,100 shares
Chief Commercial and Business
Oct 14, 2026 SEC
CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation containing information about its…
8-K — Impact 2/10
Oct 13, 2026 SEC
CervoMed reported initial 12-week biomarker data from its Phase 2a trial of neflamapimod in nfvPPA, showing a mean…
8-K — Impact 6/10
Oct 9, 2026 SEC
CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation is available on its website. The…
8-K — Impact 2/10
Sep 28, 2026 Other
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposu
Sep 10, 2026 Press
CervoMed announced that neflamapimod will be featured in a late-breaking oral presentation at the ISFTD Annual Meeting…
Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 16, 2026
Earnings date
CRVO Q3 2026 Earnings Scheduled — 2026-11-16
Recent
Sep 28, 2026
Press release
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience
Sep 22, 2026
Press release
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related…
Sep 10, 2026
FDA
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting
Sep 8, 2026
Press release
CervoMed to Participate in September Investor Conferences
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for…
Sep 3, 2026
Clinical Trial
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Phase 2 · COMPLETED

SecBot reports

19 filings · 4 press releases · 4 bullish · 7 bearish · 2 mixed · 6 neutral
All CRVO filing & press-release reports (23)